• SELECT SITE CURRENCY
Select a currency for use throughout the site
Pharmaceutical Analytical Services Outsourcing in India: Cost Savings, Product Quality and Shorter Delivery Times are Key Drivers
GBI Research, November 2010, Pages: 65
“Pharmaceutical Analytical Services Outsourcing in India: Cost Savings, Product Quality and Shorter Delivery Times are Key Drivers” provides key data, information and analysis on the pharmaceutical analytical services outsourcing in india. The report provides market landscape, competitive landscape and market trends information on the segments within the analytical services market. The report provides comprehensive information on the key trends affecting these categories, and key analytical content on the market dynamics. The report also reviews the competitive landscape, services technology offerings.
This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by a team of industry experts.
- Key geographies covered is India
- Market size and company share data the segments with pharmaceutical anlaytical laboratories market
- Annualized market revenues data from 2002 to 2009, forecast forward for 7 years to 2016. Company shares data for 2009.
- Qualitative analysis of key market trends, market drivers, and restraints by each category within the pharmaceutical analytical services market.
- The report also covers information on the leading market players, the competitive landscape, services and technologies.
Reasons to buy:
- Develop business strategies by understanding the trends and developments that are driving the Indian pharmaceutical analytical services market.
- Design and develop your product development, marketing and sales strategies.
- Exploit M&A opportunities by identifying market players with the promising products
- Develop market-entry and market expansion strategies.
- Identify key players best positioned to take advantage of the emerging market opportunities.
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return.
- What's the next being thing in the pharmaceutical analytical services market? – Identify, understand and capitalize.
- Make more informed business decisions from the insightful and in-depth analysis of the Indian pharmaceutical analytical services market and the factors shaping it.
1.1 List of Tables
1.2 List of Figures
2.1 Research Report Guidance
3.1 Major Services under Pharmaceutical Analytical Services
3.1.1 Impurity Profile
3.1.2 Analytical Method Development and Validations
3.1.3 Particle Size Distribution
4 Pharmaceutical Drug Discovery Outsourcing Market: Market Characterization
4.1 Market Share and Market Size
4.2 Pharmaceutical Drug Discovery Outsourcing Market, India, Revenue ($bn), 2004-2009
4.3 Pharmaceutical Drug Discovery Outsourcing Market, India, Revenue ($bn), 2009-2016
4.4 Forces that Drive Drug Discovery in India and China
4.4.1 Declining R&D Productivity, Especially for Big Pharma
5 Outsourcing Plan for Pharmaceutical Companies
5.1 Why India and China?
5.1.1 Availability of Skilled Manpower
5.1.2 Improved IP Protection in India and China
5.1.3 Government Support for Drug Discovery Development
5.1.4 SWOT Analysis of the Drug Discovery Industry in India
6 IP Protection in India and China – Improved IP Protection to Encourage Innovation
6.1 Patent Act 2005 – First Step towards Improving IP Protection
6.2 IPR Enforcement Rules, 2007
6.3 Trademarks Bill 2007
6.4 Drugs and Cosmetics Act (Amendment) 2008
6.5 EIPR (Enforcers of Intellectual Property Rights) – Ensuring IPR Laws Implementation in India
7 Government and Regulatory Support in India – Strong Support to Research Institutes and Small Companies
7.1 Government/Regulatory Support for Drug Discovery in India
7.1.1 Open Source Drug Discovery
7.1.2 Drug Development Promotion Board: Encouraging a PPP Model for Drug Discovery and Development
7.1.3 Technology Development Board: Supporting Technology Oriented Projects
7.1.4 NMITLI (New Millennium Indian Technology Leadership Initiative) Scheme
8 Pharmaceutical Analytical Services Outsourcing Market, Market Dynamics
8.1 Pharmaceutical Analytical Services Outsourcing Market, Market Trends
8.1.1 Pricing Pressures Driving Outsourcing of Pharmaceutical Analytical Work to Low Cost Destinations
8.1.2 Flexibility Offered by Companies in Terms of Resource and Manpower Allocation Contributing Towards Increased Outsourcing
8.1.3 Shared Risk Concept Encourages Greater Outsourcing of Drug Development
8.2 Pharmaceutical Analytical Services Outsourcing Market, Market Drivers
8.2.1 Lower Cost is a Key Driver towards Chemistry Outsourcing to Asian CROs
8.2.2 Demand for Shorter Research Cycle Driving Outsourcing of Chemistry Services
8.3 Pharmaceutical Analytical Services Outsourcing Market, Market Restraints
8.3.1 Intellectual Property and Legal Landscape is a Key Restraint in the Growth of Outsourcing of Pharmaceutical Analytical Services to Asian Countries
9 Market Opportunity and Risk Assesment
10 Future Outlook
11 Major Indian Drug Discovery Companies – Different Business Models to Provide Similar Services
11.1 Indian Drug Discovery Business Model – R&D Hive-off for Better Services and Risk Reduction
11.2 Jubilant Organosys' Jubilant Biosys
11.2.1 About Jubilant Organosys
11.2.2 Major Drug Discovery Deals
11.3 Dr. Reddy's Aurigene
11.3.1 About Dr. Reddy's
11.3.3 Major Drug Discovery Deals
11.4 Biocon's Syngene
11.4.1 About Biocon
11.4.3 Major Drug Discovery Deals
11.5 GVK BIO
11.5.1 Business Description
11.5.2 Major Drug Discovery Deals
11.6 Advinus Therapeutics
11.6.1 Business Description
11.6.2 Major Drug Discovery Deals
11.7 Sipra Labs
11.7.1 Business Description
11.8 Sai Advantium
11.8.1 Business Description
12 Deals Analysis – Equal Thrust From Big Pharma and Mid-Size Pharma
12.1 Number of Discovery Research Deals – Increased Activity by Big and Mid-size Pharma
12.2 Deals by Major Therapeutic Area – Oncology and Metabolic Disorders
12.3 Deals by Client Type – Mid-size Pharma Deals Rising in India and China
12.4 Major Drug Discovery Deals
12.4.1 Amgen with Jubilant Biosys: Supporting Early Stage Preclinical Development Effort to Provide Cost-Effective Drugs
12.4.2 Bristol-Myers Squibb with Syngene: Dedicated Research Facility for Discovery and Early Drug Development
12.4.3 Novartis with Aurigene: Generating Pre-clinical Candidates for Oncology-focused Program
12.4.4 Merck & Co with Advinus Therapeutics: To Develop Clinically Validated Drug Candidates for Metabolic Disorders
13 Future Challenges – Financial and Intellectual Obstacles to Impede the Future Growth
13.1 Financial Problems will Make it Difficult to Sustain the Growth
13.2 Talent Shortage in Early Stage Chemistry and Biology
13.3 Competition from Europe as an Alternative Discovery Research Destination
14 Key Takeaway
15.2 Market Definitions
15.4 Research Methodology
15.4.1 Secondary Research
15.4.2 Primary Research
15.4.5 Expert Panels
15.5 Contact Us
1.1 List of Tables
Table 1: Pharmaceutical Drug Discovery Outsourcing Market, India, Revenue ($bn), 2004-2009
Table 2: Pharmaceutical Drug Discovery Outsourcing Market, India, Revenue ($bn), 2009-2016
Table 3: SWOT Analysis – Drug Discovery Market in India
1.2 List of Figures
Figure 1: Drug Discovery Research
Figure 2: Fully Integrated Pharmaceutical Network
Figure 3: Pharmaceutical Drug Discovery Outsourcing Market, India, Revenue ($bn), 2004-2009
Figure 4: Pharmaceutical Drug Discovery Outsourcing Market, India, Revenue ($bn), 2009-2016
Figure 5: Global Drug Discovery Market, Market Breakdown by Value, 2008
Figure 6: Comparison of CAGR of R&D Expenditure versus Turnover for the Top 5 Pharmaceutical Companies, 2004–2008
Figure 7: Increasing Cost of Introducing an NME in the US
Figure 8: Outsourcing Map for Pharmaceutical Companies
Figure 9: Different Types of Cooperation Models for Outsourced Services
Figure 10: India & China Talent Pool – Comparison
Figure 11: Number of Patent Applications Originating from China and India, 2004–2008
Figure 12: Intellectual Property Rights in India
Figure 13: Open Source Drug Discovery Activity Map
Figure 14: Technology Development Board Financial Assistance, India, Value Breakdown by Sector, 1997–2007
Figure 15: Traditional Outsourcing Model
Figure 16: Strategic Partnership Model
Figure 17: Business Models, Indian Drug Discovery Companies
Figure 18: Jubilant – Corporate Profile
Figure 19: Dr. Reddy's – Corporate Profile
Figure 20: Biocon – Corporate Profile
Figure 21: GVK BIO – Corporate Profile
Figure 22: Advinus Therapeutics – Corporate Profile
Figure 23: Sipra Labs - Corporate Profile
Figure 24: Sai Advantium - Corporate Profile
Figure 25: Number of Major Discovery Research Deals by Country, India and China, 2006–2009
Figure 26: Percentage of Major Discovery Research Deals by Therapeutic Area, India and China, 2006–2009
Figure 27: Number of Major Discovery Research Deals in India and China by Client Company Type, 2006–2009
Figure 28: Top 5 Big Pharma Companies by Number of Deals in India and China, 2006–2009
“Pharmaceutical Analytical Services Outsourcing in India: Cost Savings, Product Quality and Shorter Delivery Times are Key Drivers” provides key data, information and analysis on the pharmaceutical analytical services outsourcing in india. The report provides market landscape, competitive landscape and market trends information on the segments within the analytical services market. The report provides comprehensive information on the key trends affecting these categories, and key analytical content on the market dynamics. The report also reviews the competitive landscape, services technology offerings. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by a team of industry experts.
Pharmaceutical Drug Discovery Outsourcing Market, Revenue ($bn), 2009-2016
With growing reliance on Indian pharmaceutical and biotech companies for drug discovery, the future drug discovery market in India is expected to grow strongly. According to GBI Research, the drug discovery market in India was $650m in 2009, representing a Compound Annual Growth Rate (CAGR) of 60% from 2004, and the market is expected to grow to reach $2.24 billion by 2016. The major factors driving this growth include: huge cost advantages for the Western pharmaceutical companies of up to 60–70%, favorable local regulatory conditions to promote drug discovery, improved IP (Intellectual Property) protection after the introduction of TRIPS (Trade-Related Aspects of Intellectual Property Rights), skilled workforce and Western-equivalent research infrastructure.
Government/Regulatory Support for Drug Discovery in India
Government support in India for the development of the drug discovery and development market has been largely focused on the purchasing power parity (PPP) model. Unlike China, the government in India has encouraged private entrepreneurship by helping the private biotech and pharmaceutical companies in their projects through collaborative research, loans or grant-in-aid.
The Department of Science and Technology leads the government initiatives for encouraging research and development R&D in the country, which has largely benefited the healthcare and pharmaceutical industry. The conceptualization, implementation and monitoring of the majority of the government's initiatives has been handled by Council of Scientific and Industrial Research (CSIR). The department established several bodies, such as the Drug Development Promotion Board and the Technology Development Board, in order to provide funding for research projects across different sectors. These bodies have entered into collaborations with a number of drug discovery and development projects with Indian pharmaceutical companies. The agencies are also collaborating with various national level research institutes and universities across the country.
A sample for this product is available. Please Login/Register to download this sample.